We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback